Sign in
Not yet taking people in ItalyPhase 2

Preventing blood clots in people with liver cirrhosis and liver cancer

Tests a blood-thinning injection to prevent clots in adults with cirrhosis and liver cancer.

Key facts

Who runs it
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Where
Padova and Rome, ItalySee the 2 sites
Registry title
Prevention of venous thromboembolism in cirrhotic patients with hepatocellular carcinoma
Status
Not yet recruiting
Phase
Phase 2
People taking part
70 people, planned
Started
1 Oct 2026
Expected to end
1 Oct 2029
Type of study
Interventional
Record updated
17 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with liver cirrhosis, high pressure in the liver's blood vessels (CSPH) and liver cancer (HCC) of 5 cm³ or more, who are planned for local treatment of the tumour. It tests whether a blood thinner (LMWH) prevents blood clots.

Age
18 years or older
Sex
Men and women can join
Disease stage
Liver cirrhosis of any cause, with CSPH and hepatocellular carcinoma (HCC) with a tumour volume (TTV) of 5 cm³ or more, who are candidates for locoregional treatments
Earlier treatment
People currently on blood-thinning (anticoagulant) therapy cannot join. No prior treatment is required.

Main reasons for not taking part

  • A blood clot (venous thromboembolism) now or in the past
  • Major bleeding in the past, or bleeding related to portal hypertension in the last 3 months
  • Severe liver dysfunction (Child-Pugh class C) or INR above 2
  • Severe kidney failure (GFR below 30 mL/min) or platelet count below 30,000/mm³
  • Pregnancy or breastfeeding

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Written informed consent
  • ability and willingness to comply with the protocol
  • adults (≥ 18 years)
  • male or female participants
  • liver cirrhosis of any etiology
  • CSPH
  • HCC with TTV > or = 5 cm³, candidates for locoregional treatments

Who cannot take part

  • history of prior venous thromboembolic events
  • current anticoagulant therapy
  • participation in another clinical trial in which an investigational drug was administered within 30 days prior to screening or within 5 half-lives of the study drug, whichever is longer
  • current or previous immune-mediated heparin-induced thrombocytopenia (HIT type II)
  • hypersensitivity to tinzaparin or to any of the excipients
  • history of major bleeding defined as bleeding occurring in a critical site (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, intrauterine, or intramuscular with compartment syndrome)
  • recent portal hypertension-related bleeding (< 3 months)
  • evidence of venous thromboembolism event at baseline
  • active malignancy other than HCC
  • international normalized ratio (INR) > 2
  • congenital coagulation or platelet disorder
  • severe renal failure (GFR <30 mL/min)
  • platelet count <30,000/mm³
  • current septic endocarditis
  • severe liver dysfunction (Child-Pugh class C)
  • hepatic encephalopathy of a severity that precludes the ability to provide informed consent (West Haven grade ≥2)
  • poor prognosis (estimated survival time of less than 12 months)
  • pregnancy or breastfeeding

Where in Italy

  • Azienda Ospedaliera di PadovaPadova, ItalyNot yet recruiting
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCSRome, ItalyNot yet recruiting

About the trial

What the trial wants to find out

To explore the efficacy of prophylactic LMWH therapy in preventing thrombotic events in consecutive adult participants with cirrhosis of any etiology, CSPH, and HCC with a TTV of > or = 5 cm³, who are candidates for locoregional treatments, without evidence of thrombosis at the time of enrollment

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Prevention of venous thromboembolism in cirrhotic patients with hepatocellular carcinoma
Plain-language title
Preventing blood clots in people with liver cirrhosis and liver cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
17 September 2026